✦ LIBER ✦

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

✍ Scribed by Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J. Racewicz; Ronald F. van Vollenhoven; Nicole F. Li; Sunil Agarwal; Eva W. Hessey; Timothy M. Shaw

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 228 KB
Volume: 54
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.21778

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Golimumab in patients with active rheuma

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

✍ Jonathan Kay; Eric L. Matteson; Bhaskar Dasgupta; Peter Nash; Patrick Durez; Ste 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

Erratum: Golimumab in patients with acti

Erratum: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

✍ Jonathan Kay; Eric L. Matteson; Bhaskar Dasgupta; Peter Nash; Patrick Durez; Ste 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 2 views

Efficacy of methotrexate treatment in pa

Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial

✍ Henrike van Dongen; Jill van Aken; Leroy R. Lard; Karen Visser; H. Karel Ronday; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## Objective To determine whether patients with undifferentiated arthritis (UA; inflammatory, nontraumatic arthritis that cannot be diagnosed using current classification criteria) benefit from treatment with methotrexate (MTX). ## Methods The PRObable rheumatoid arthritis: Methotrex

Efficacy and safety of golimumab in pati

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

✍ Robert D. Inman; John C. Davis Jr.; Désirée Van Der Heijde; Laura Diekman; Joach 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 1 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1

Treatment of rheumatoid arthritis with t

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

✍ Joel M. Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; Willia 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

Treatment of rheumatoid arthritis with t

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

✍ Joel M. Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; Willia 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig), a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has remained active despite methotrexate (MTX) therapy. ## Methods This was a 12‐month, multicente